ResearchBib Share Your Research, Maximize Your Social Impacts
Sign for Notice Everyday Sign up >> Login

The Effect of Salmeterol, Tiotropium Bromide and its Combination in Patients with Acute Exacerbation Of Chronic Obstructive Pulmonary Disease

Journal: International Journal of Respiratory Disease, Care & Medicine (IJRDM) (Vol.4, No. 1)

Publication Date:

Authors : ;

Page : 54-58

Keywords : Acute Exacerbated COPD; Salmeterol; Tiotropium Bromide; FEV1; FVC.;

Source : Downloadexternal Find it from : Google Scholarexternal

Abstract

Background: In order to managing patients with acute exacerbated COPD, long-acting anticholinergic drugs and long-acting beta-agonists are used alone. Therefore, the purpose of this study was to investigate the effect of salmeterol, tiotropium bromide and its combination in patients with acute exacerbation of chronic obstructive pulmonary disease. Materials and Methods: This tripartite clinical trial study was performed on patients with acute exacerbated COPD referred to the Emergency Department of Shahid Beheshti Hospital of Kashan in 2019 (135 people). Patients were randomly divided into three groups. For each of the three groups, salmeterol sprays, tiotropium bromide and combination were administered separately during the admission. FEV1 and FVC measures were evaluated before and after the intervention for all three groups via spirometry. Data were analyzed using chi-square test, ANOVA, paired t-test and covariance analysis. Results: The results of covariance analysis (age variables and pre-intervention as covet) indicated a significant difference between the three groups of salmeterol (60/137), tiova (98/98) and combination 0f both medications(167.64) in terms of FEV1 variable (P <0.001) and between the three groups of salmeterol (146.41), tiova (12.51) and combination (29.22) in terms of FVC variable (p <0.001). Conclusion: The findings of this study confirm the significant impact of combination of two long-acting bronchodilators with different pharmacological mechanisms in patients who need two drug classes for control of their disease is effective for them.

Last modified: 2021-10-28 16:34:52